Franklin Resources Inc. Trims Stake in Jazz Pharmaceuticals PLC $JAZZ

Franklin Resources Inc. lessened its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 6.9% in the second quarter, HoldingsChannel reports. The firm owned 706,634 shares of the specialty pharmaceutical company’s stock after selling 52,093 shares during the quarter. Franklin Resources Inc.’s holdings in Jazz Pharmaceuticals were worth $74,988,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Hurley Capital LLC purchased a new stake in Jazz Pharmaceuticals in the first quarter worth $25,000. Picton Mahoney Asset Management boosted its holdings in shares of Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after buying an additional 269 shares in the last quarter. SVB Wealth LLC bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter valued at $36,000. Hantz Financial Services Inc. grew its position in shares of Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 297 shares during the period. Finally, Geneos Wealth Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Trading Up 2.2%

Shares of NASDAQ JAZZ opened at $180.90 on Tuesday. The firm’s 50 day moving average price is $139.97 and its 200-day moving average price is $123.16. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The company has a market cap of $10.99 billion, a PE ratio of -26.88, a P/E/G ratio of 8.49 and a beta of 0.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, beating the consensus estimate of $5.87 by $2.26. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company’s revenue was up 6.7% compared to the same quarter last year. During the same period last year, the business posted $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 18,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $181.09, for a total value of $3,259,620.00. Following the completion of the sale, the director directly owned 390,826 shares in the company, valued at approximately $70,774,680.34. This trade represents a 4.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 5,319 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $182.06, for a total transaction of $968,377.14. Following the transaction, the chief accounting officer owned 7,012 shares in the company, valued at $1,276,604.72. This represents a 43.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 50,893 shares of company stock valued at $8,559,699 over the last three months. 4.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JAZZ. Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the company an “outperform” rating in a research report on Monday, November 17th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. UBS Group reissued a “neutral” rating and issued a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday. JPMorgan Chase & Co. cut their price target on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $195.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.